https://www.selleckchem.com/pr....oducts/cid44216842.h
75; P = 0.001) were prognostic factors for OS. Patients with oligometastasis (P = 0.009) and those with IMDC favorable (P = 0.044) or intermediate (P = 0.002) risk had significantly longer OS with TKI + SBRT. The median TTS were 21.5, 6.4, and 9.0 months in patients receiving SBRT before first-line TKI failure, SBRT after first-line TKI failure, and first-line TKI alone (P 0.001). Five patients (5.9%) experienced SBRT-related grade 3 toxicities. Combining SBRT with TKIs is tolerable and associated with longer OS in selected pat
Like
Comment
Share
